- Biosensor medical device contains company’s biochip
- Beta prototype biosensor suitable for preclinical validation
- Prototype is being developed as a robust user-ready, manufacturable system
- Biosensor a potential platform suitable for applications beyond potassium sensing.
Quantum technologies company Archer Materials (ASX: AXE) has continued to progress development of its biosensor beta prototype for blood potassium sensing and expansion into other diagnostic applications.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Earlier this year the company successfully demonstrated its integrated alpha prototype which achieved clinical-grade potassium sensing accuracy within a fully integrated prototype system comprising the biochip, microfluidics and readout electronics
CEO, Dr Simon Ruffell, said the company has now advanced to the next stage of product development through construction of its beta prototype biosensor platform.
“The beta prototype program is focused on developing a more refined, user-ready, and manufacturable diagnostic system suitable for external validation, future clinical studies, and commercial deployment pathways. This includes advancement of the cartridge design, handheld electronics, biochip integration, and sensing platform into a more refined and manufacturable diagnostic system,” Dr Ruffell said.
“Importantly, we are also expanding engagement with IMEC and manufacturing partners to support future scale-up and commercialisation opportunities.
“We are encouraged by the early feasibility testing underway for additional applications, including lithium monitoring in blood which may broaden the long-term commercial potential of the Biochip platform.
“We believe the ongoing engineering and production progress continues to significantly de- risk the biosensor and biochip technology and positions Archer well for the next stage of external validation and commercial discussions.”
Dr Ruffell said the beta prototype program represents an important step toward external validation, future clinical studies and commercial partnership development.
He told shareholders Archer plans to develop multiple versions of the beta prototype with ongoing refinements informed by external testing, studies and validation activities.
The first beta prototype system is expected to become available for testing in the coming months, with additional optimisation and validation planned throughout the second half of 2026, with the target of a fully optimised beta prototype for use in trials in 2027.
AXE is up 3.12% to 33.0¢. Mkt cap $81.55M.
Join the discussion: See what Hot Copper users are saying about Archer Materials and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.